Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (41): 7677-7680.doi: 10.3969/j.issn.2095-4344.2012.41.016

Previous Articles     Next Articles

Different transplantation approaches of bone marrow mesenchymal stem cells in a rat model of cirrhosis

Wu Yu-zhuo   

  1. Department of Infection and Hepatopathy, Nanyang Central Hospital, Nanyang 473000, Henan Province, China
  • Received:2011-12-26 Revised:2012-01-20 Online:2012-10-07 Published:2012-10-07
  • About author:Wu Yu-zhuo★, Master, Attending physician, Department of Infection and Hepatopathy, Nanyang Central Hospital, Nanyang 473000, Henan Province, China angel_060@126.com

Abstract:

BACKGROUND: Transplantation of bone marrow mesenchymal stem cells can alleviate cirrhosis and improve liver function.
OBJECTIVE: To investigate the differences among the curative effects of three transplantation approaches of mesenchymal stem cells (MSCs) in a rat model of cirrhosis.
METHODS: 60 SD rats were randomly divided into five groups: normal, control, portal vein transplantation, hepatic artery transplantation and tail vein transplantation groups. The rat model of CC14 and alcohol-induced cirrhosis was prepared in the latter four groups. Rats in the portal vein transplantation, hepatic artery transplantation and tail vein transplantation groups received 1×106 allogenic rat bone marrow mesenchymal stem cells via the portal vein, hepatic artery and tail vein, respectively. The control group rats received no transplantation.
RESULTS AND CONCLUSION: Compared with the control group, the liver function of cirrhosis rats in the three transplantation groups was improved significantly, the levels of serum albumin and cholinesterase were significantly increased (P < 0.05), the levels of transaminases, bilirubin, prothrombin time, type IV collagen were significantly decreased, and the degree of cirrhosis was significantly alleviated (P < 0.05) at 4 weeks after transplantation in the three transplantation groups. The outcomes were significantly superior in the portal vein transplantation and hepatic artery transplantation groups than in the tail vein transplantation group (P > 0.05). These findings suggest that portal vein transplantation and hepatic artery transplantation can better alleviate the degree of cirrhosis and improve hepatic function than tail vein transplantation, and there is no significant difference between the former two groups.

CLC Number: